These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
682 related articles for article (PubMed ID: 11223973)
21. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease. Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886 [TBL] [Abstract][Full Text] [Related]
22. The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia. Sloand E; Childs RW; Solomon S; Greene A; Young NS; Barrett AJ Bone Marrow Transplant; 2003 Nov; 32(9):897-901. PubMed ID: 14561990 [TBL] [Abstract][Full Text] [Related]
23. Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients. Heining C; Spyridonidis A; Bernhardt E; Schulte-Mönting J; Behringer D; Grüllich C; Jakob A; Bertz H; Finke J Bone Marrow Transplant; 2007 May; 39(10):613-22. PubMed ID: 17384658 [TBL] [Abstract][Full Text] [Related]
24. Immunological reconstitution and correlation of circulating serum inflammatory mediators/cytokines with the incidence of acute graft-versus-host disease during the first 100 days following unrelated umbilical cord blood transplantation. Abu-Ghosh A; Goldman S; Slone V; van de Ven C; Suen Y; Murphy L; Sender L; Cairo M Bone Marrow Transplant; 1999 Sep; 24(5):535-44. PubMed ID: 10482939 [TBL] [Abstract][Full Text] [Related]
25. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia]. Liu QF; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032 [TBL] [Abstract][Full Text] [Related]
26. Flow cytometric characterization of human umbilical cord blood lymphocytes: immunophenotypic features. D'Arena G; Musto P; Cascavilla N; Di Giorgio G; Fusilli S; Zendoli F; Carotenuto M Haematologica; 1998 Mar; 83(3):197-203. PubMed ID: 9573672 [TBL] [Abstract][Full Text] [Related]
27. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report. Saikia TK; Parikh PM; Tawde S; Amare-Kadam PS; Rajadhyaksha S; Chhaya S Natl Med J India; 2004; 17(2):71-3. PubMed ID: 15141598 [TBL] [Abstract][Full Text] [Related]
28. [HLA-identical sibling allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia in first chronic phase. Analysis of 51 cases]. He Y; Feng SZ; Wang M; Wei JL; Qin TJ; Zhou Z; Zhai WJ; Qiu LG; Han MZ Zhonghua Xue Ye Xue Za Zhi; 2005 Jul; 26(7):389-92. PubMed ID: 16251016 [TBL] [Abstract][Full Text] [Related]
29. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase. Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121 [TBL] [Abstract][Full Text] [Related]
30. Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study. Joshi SS; Bishop MR; Lynch JC; Tarantolo SR; Abhyankar S; Bierman PJ; Vose JM; Geller RB; McGuirk J; Foran J; Bociek RG; Hadi A; Day SD; Armitage JO; Kessinger A; Pavletic ZS Cytotherapy; 2003; 5(6):542-52. PubMed ID: 14660050 [TBL] [Abstract][Full Text] [Related]
31. Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics. Porta MD; Rigolin GM; Alessandrino EP; Maiocchi M; Malcovati L; Vanelli L; Baratè C; Rumi E; Ciccone M; Cuneo A; Lazzarino M; Castoldi G Eur J Haematol; 2004 Jan; 72(1):18-25. PubMed ID: 14962258 [TBL] [Abstract][Full Text] [Related]
32. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR; Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337 [TBL] [Abstract][Full Text] [Related]
33. Non-CD34+ cells, especially CD8+ cytotoxic T cells and CD56+ natural killer cells, rather than CD34 cells, predict early engraftment and better transplantation outcomes in patients with hematologic malignancies after allogeneic peripheral stem cell transplantation. Kim DH; Won DI; Lee NY; Sohn SK; Suh JS; Lee KB Biol Blood Marrow Transplant; 2006 Jul; 12(7):719-28. PubMed ID: 16785061 [TBL] [Abstract][Full Text] [Related]
34. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Lilleri D; Fornara C; Chiesa A; Caldera D; Alessandrino EP; Gerna G Haematologica; 2008 Feb; 93(2):248-56. PubMed ID: 18245650 [TBL] [Abstract][Full Text] [Related]
35. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma. Saito T; Kanda Y; Kami M; Kato K; Shoji N; Kanai S; Ohnishi T; Kawano Y; Nakai K; Ogasawara T; Matsubara H; Makimoto A; Tanosaki R; Tobinai K; Wakasugi H; Takaue Y; Mineishi S Clin Cancer Res; 2002 Apr; 8(4):1014-20. PubMed ID: 11948108 [TBL] [Abstract][Full Text] [Related]
36. Reconstitution of the CD45RO(+) and CD20(+) lymphoid marrow population following allogeneic bone marrow transplantation for Ph(+) CML. Thiele J; Kvasnicka HM; Beelen DW; Welter A; Schneider S; Leder LD; Schaefer UW Bone Marrow Transplant; 2001 Feb; 27(4):425-31. PubMed ID: 11313672 [TBL] [Abstract][Full Text] [Related]
37. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma. Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737 [TBL] [Abstract][Full Text] [Related]
38. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase. Elmaagacli AH; Runkel K; Steckel N; Opalka B; Trenschel R; Seeber S; Schaefer UW; Beelen DW Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437 [TBL] [Abstract][Full Text] [Related]
39. Reduced-intensity conditioning for allogeneic stem cell transplantation in patients with chronic myeloid leukemia is associated with better overall survival but inferior disease-free survival when compared with myeloablative conditioning - a retrospective study of the Czech National Hematopoietic Stem Cell Transplantation Registry. Faber E; Koza V; Vitek A; Mayer J; Sedlacek P; Zak P; Zapletalova J; Benesova K; Krejcova H; Steinerova K; Maresova I; Cetkovsky P; Neoplasma; 2007; 54(5):443-6. PubMed ID: 17688375 [TBL] [Abstract][Full Text] [Related]
40. [Effects of graft compositions on hematopoietic reconstitution and graft-versus-host disease in related donor peripheral blood stem cell transplantation]. Zhan Y; Yi ZS; Wei YQ; Huang F; Zhang YM; Fan ZP; Feng R Zhonghua Xue Ye Xue Za Zhi; 2008 May; 29(5):333-6. PubMed ID: 18844073 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]